Table 3.
Distribution of monocytes and expression of CD35 and CD59 on monocytes and subsets.
| nAMD n = 29 | iAMD n = 28 | MPNd (n = 35) | MPNn (n = 27) | P-value 1 testing between MPN groups | P-value 2 testing between all groups | |
|---|---|---|---|---|---|---|
| Monocytes,%, median (IQR) | 3·7 (2·4–4·6) | 3·9 (2·7–4·9) | 2·8 (2·1–3·6) | 3·0 (2·1–3·4) | 0·67d | 0·073a |
| CD35%, median (IQR) | 72 (62–83) | 77 (68–82) | 76 (67–80) | 80 (67–85) | 0·30d | 0·58a |
| CD59%, median (IQR) | 72 (64–94) | 68 (54–78) | 50 (33–75) | 65 (49–80) | 0·13d | 0·0040a |
| Classical monocytes (CD14highCD16low),% median (IQR) | 83 (78–88) | 84 (80–86) | 77 (70–84) | 82 (75–88) | 0·10d | 0·016a |
| CD35%, median (IQR) | 83 (71–92) | 87 (79–93) | 91 (80–94) | 90 (80–93) | 0·73d | 0·45a |
| CD59%, median (IQR) | 82 (68–96) | 71 (56–83) | 53 (35–84) | 71 (53–82) | 0·20d | 0·0059a |
| Intermediate monocytes(CD14highCD16high),% mean (95%CI) | 6·8 (5·5–8·4) | 7·5 (6·1–9·1) | 12 (9·6–15) | 10 (8·3–13) | 0·31d | <0·001b |
| CD35%, median (IQR) | 40 (24–55) | 47 (27–61) | 45 (33–60) | 53 (37–60) | 0·49d | 0·22a |
| CD59%, median (IQR) | 69 (53–93) | 62 (50–81) | 49 (33–70) | 60 (44–81) | 0·16d | 0·013a |
| Non-classical monocytes (CD14lowCD16high)% mean (95%CI) | 7·6 (6·2–9·3) | 8·9 (7·7–10) | 8·4 (6·7–12) | 7·3 (5·8–9·2) | 0·48d | 0·13c |
| CD35%, median (IQR) | 2·2 (1·2–3·7) | 4·0 (1·8–6·2) | 3·4 (1·1–7·1) | 2·9 (1·5–5·2) | 0·92d | 0·34a |
| CD59%, median (IQR) | 26 (19–73) | 24 (19–36) | 18 (13–40) | 28 (18–42) | 0·16d | 0·062a |
P-values in bold are significant. Statistical comparisons between groups:
a
Kruskal Wallis test.
b
One-way ANOVA.
c
Two-way ANOVA.
d
Wilcoxon rank-sum test.
eindependent samples t-test
IQR: interquartile range; 95%CI: 95% confidence interval; MPN: myeloproliferative neoplasms; nAMD: neovascular age-related macular degeneration; iAMD: intermediate age-related macular degeneration.